Impotence News and Research

RSS

Erectile dysfunction, sometimes called "impotence," is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word "impotence" may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved.

First Edition: October 7, 2011

In today's headlines, reports about what the Institute of Medicine recommends in terms of the criteria and methods the Department of Health and Human Services should follow in developing the health law's essential benefits package.

7 Oct 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

Cancer prevention tips for men at every stage of life

Men who maintain a healthy body throughout life are often better able to fight off diseases like cancer. That's why experts at The University of Texas MD Anderson Cancer Center have created a guide with cancer prevention tips to help men at every stage of life.

13 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Researchers identify five SNPs linked with aggressive, lethal prostate cancer

An international team of researchers led by Fred Hutchinson Cancer Research Center has identified five inherited genetic variants that are strongly associated with aggressive, lethal prostate cancer.

17 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

Russia aiming to cut number of smokers by 15% by 2050

Russia is aiming to cut the number of smokers in the country by up to 15 percent by 2050, "huge ambitions considering 40 percent of Russians light up," VOA News reports.

27 Jul 2011

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

USHIFU announces results from clinical investigation of Sonablate HIFU to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.

30 Apr 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

New study: Many elderly men may overuse PSA testing

A new study on the use of prostate-specific antigen-based prostate cancer screening in the United States found that many elderly men may be undergoing unnecessary prostate cancer screenings.

29 Mar 2011

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

The Focused Ultrasound Surgery Foundation has released a special men's heath update in its February 2011 online newsletter.

23 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

XYTOS shares cancer patient treatment results

XYTOS Shares Patient Results.

28 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010